A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease
Status:
Recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
NOPARK is a double-blinded randomized controlled trial that studies nicotinamide
supplementation in early Parkinson's disease.
Parkinson's disease (PD) is a major cause of death and disability and has a worldwide
socioeconomic impact. It affects ~2% of the population above the age of 65 years and its
prevalence increases dramatically as the population ages. The etiology and molecular
pathogenesis underlying PD remain unknown. Recent evidence has implicated an impaired
neuronal metabolism due to mitochondrial dysfunction, in particular NAD-deficiency is a
key-event in the pathogenesis of PD. We propose that in order to correct this metabolic
defect and treat PD, we need to boost neuronal NAD levels. This would improve mitochondrial
function and could slow PD progression. Nicotinamide riboside is a precursor NAD vitamin. In
this study we will investigate if nicotinamide riboside supplementation will correct NAD
deficiency and thereby slow progression of PD symptoms. This study will recruit 200 patients
with newly diagnosed PD and randomly assign them in an 1:1 ratio to either nicotinamide
riboside or placebo administration for 52 weeks. During this trial the investigators will
determine if nicotinamide riboside delays PD disease progression measured by clinical
monitoring tools (MDS-UPDRS). Patients receiving nicotinamide riboside supplementation will
receive a daily dose of 1000mg for the duration of the trial. This trial will also collect
biological material from participants to see if nicotinamide riboside supplementation
rectifies NAD deficiency and metabolism deficiencies.